The Open-Angle Glaucoma drugs in development market research report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Open-Angle Glaucoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued products.
GlobalData tracks 57 drugs in development for Open-Angle Glaucoma by 48 companies/universities/institutes. The top development phase for Open-Angle Glaucoma is phase ii with 21 drugs in that stage. The Open-Angle Glaucoma pipeline has 55 drugs in development by companies and two by universities/ institutes. Some of the companies in the Open-Angle Glaucoma pipeline products market are: Santen Pharmaceutical, Laboratoires Thea and Q BioMed.
The key targets in the Open-Angle Glaucoma pipeline products market include Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR), Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1), and Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2).
See Also:
The key mechanisms of action in the Open-Angle Glaucoma pipeline product include Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR) Agonist with 18 drugs in Pre-Registration. The Open-Angle Glaucoma pipeline products include seven routes of administration with the top ROA being Ophthalmic and seven key molecule types in the Open-Angle Glaucoma pipeline products market including Small Molecule, and Recombinant Protein.
Open-Angle Glaucoma overview
Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to a buildup of aqueous humor (fluid) and an increase in intraocular pressure. Elevated pressure damages the optic nerve, which transmits visual information to the brain, causing gradual vision loss. Risk factors include age (more common in individuals over 40), family history of glaucoma, high IOP, certain medical conditions (such as diabetes and hypertension), and certain ethnicities (African Americans have a higher risk). Early-stage, open-angle glaucoma often presents without noticeable symptoms or vision changes. As the condition progresses, peripheral vision loss (usually unnoticed at first) gradually advances to tunnel vision and, if untreated, can lead to complete blindness.
For a complete picture of Open-Angle Glaucoma’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
